EMCDDA Home
  • EN
Search

Country overview: Spain

Key statistics on the drug situation in Spain

  Indicator Year (0)   Country
data
EU range  
Min. Max.
Lifetime prevalence of drug use among young adults (15 to 34 years old) cannabis GPS 2009   42.4 % 2.9 % 45.5 % 1
Lifetime prevalence of drug use among all adults (15 to 64 years old) cannabis 2009   32.1 % 1.5 % 32.5 % 1
Last year prevalence of drug use among young adults (15 to 34 years old) cannabis 2009   19.4 % 0.9 % 21.6 % 1
Last year prevalence of drug use among all adults (15 to 64 years old) cannabis 2009   10.6 % 0.4 % 14.3 % 1
Lifetime prevalence of drug use among young adults (15 to 34 years old) cocaine 2009   13.6 % 0.1 % 13.6 % 1
Lifetime prevalence of drug use among all adults (15 to 64 years old) cocaine 2009   10.2 % 0.1 % 10.2 % 1
Last year prevalence of drug use among young adults (15 to 34 years old) cocaine 2009   4.4 % 0.1 % 4.8 % 1
Last year prevalence of drug use among all adults (15 to 64 years old) cocaine 2009   2.7 % 0 % 2.7 % 1
Recent school surveys: lifetime prevalence (15 to 16 years old) cannabis EYE 2008 a 33 % 4 % 45 % 2
Recent school surveys: lifetime prevalence (15 to 16 years old) cocaine 2008 a 4 % 1 % 5 % 2
Problem drug use rate per 1 000 population aged 15 to 64 years old PDU 2008   1.3 0.5 10.1 1
Injecting drug use rate per 1 000 population aged 15 to 64 years old       0.22 15.1 1
Infectious diseases (% infected) HIV INF 2008   32.5 % 0 % 32.5 % 1
Infectious diseases (cases per million) HIV infections newly diagnosed in injecting drug users 2009 b 6.4 0 63.4 5
Infectious diseases (% infected) HCV       22.4 % 90.7 % 1
Infectious diseases (% infected) HBV HBsAg       0.5 % 3.9 % 1
Drug-related deaths DRD 2008   540 6 2 481 3
Drug law offences (as number of reports of offences) DLO 2009   397 620 772 397 620 2
Drug law offences for use/possession 2009   372 230 285 372 230 1
Cannabis drug law offences i 2009 c 81.3 % 24.4 % 91.5 % 4
Number of new clients entering treatment TDI 2008   22 944 21 45 048 3
Number of new clients entering treatment with known primary drug 2008   22 944 0 43 683 3
New clients entering treatment (% opioids of clients with known primary drug) 2008   17.7 % 3.1 % 92.8 % 3
New clients entering treatment (% cocaine of clients with known primary drug) 2008   56 % 0 % 56 % 3
New clients entering treatment (% cannabis of clients with known primary drug) 2008   22 % 1.9 % 80.2 % 3
Number of all clients entering treatment 2008   53 155 350 139 390 3
Number of all clients entering treatment with known primary drug 2008   53 155 350 133 960 3
All clients entering treatment (% opioids of clients with known primary drug) 2008   36.4 % 10.4 % 97.1 % 3
All clients entering treatment (% cocaine of clients with known primary drug) 2008   46.4 % 0.1 % 46.4 % 3
All clients entering treatment (% cannabis of clients with known primary drug) 2008   14 % 0.6 % 69.8 % 3
Syringes provided through needle and syringe programmes HSR 2009   3 421 518 0 4 861 195 1
Number of all clients in substitution treatment 2008   81 425 189 137 541 2
Price in euros per gram cannabis herb ii PPP 2009   EUR 3.60 EUR 2 EUR 70 5
Price in euros per gram cannabis resin ii 2009   EUR 4.80EUR 3 EUR 19 5
Price in euros per gram cocaine ii 2009   EUR 59.60 EUR 45 EUR 104 5
Price in euros per gram heroin (brown) ii;iv 2009   EUR 61.80EUR 23 EUR 135 5
Price in euros 1 tablet XTC ii 2009   EUR 10.20 EUR 3 EUR 15.90 5
Price in euros per gram amphetamine ii 2009   EUR 26.20 EUR 8 EUR 41.80 5
Purity (%) cocaine iii 2009   49 % 18 % 51.3 % 5
Purity (%) heroin (brown) iii 2009   31.5 % 12.9 % 37 % 5
Potency (%) cannabis resin iii;v       2.9 % 17.3 % 5
Potency (%) cannabis herb iii       1.3 % 12.4 % 5

Notes

i As percentage of all drug law offences reported.

ii When available, country provides minimum, maximum, mean, median and modal (most frequent) price in euros recorded. This table shows the mean price in euros.

iii When available, country provides minimum, maximum, mean, median and modal (most frequent) purity/potency (percentage). This table shows the mean purity/potency (percentage).

iv The minimum value in the European range refers to the mean price.

v The maximum value in the European range refers to the mean potency.

0 Most recent available data shown. Any data prior to 2005 not shown.

1 2005 to 2009 data.

2 2007 to 2009 data.

3 2008 to 2009 data.

4 2006 to 2009 data.

5 2009 data.

a Spain did not participate in the ESPAD survey. ESPAD methods are adopted to varying degrees.

b Data are available for 15 regions.

c Based on numbers of mentions of cannabis among all drug mentions, whether alone or with other drugs.

 

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>

Contact us

EMCDDA
Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Monday, 14 November 2011